Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.78 USD

73.78
5,148,046

-0.56 (-0.75%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Company News for Jun 9, 2020

Companies In The News Are: THO, ROKU, GILD, AZN, TSLA.

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?

AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment

AbbVie (ABBV) collaborates with three parties for developing an antibody-based treatment for COVID-19.

Ritujay Ghosh headshot

Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus

Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.

AstraZeneca Reportedly Approaches Gilead for Potential Merger

If AstraZeneca (AZN) and Gilead (GILD) were to combine into one, it would be the biggest health-care deal ever.

Gilead's Rating Upgraded on Potential Coronavirus Drug Sales

Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.

Roche's COVID-19 Test Gets FDA's Emergency Use Authorization

Roche's (RHHBY) Elecsys IL-6 test gets FDA's EUA for identifying patients at high risk of severe inflammatory response.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to Coronavirus Treatment News?

Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.

Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

Lilly Begins Coronavirus Study to Evaluate Antibody Therapy

Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.

Gilead Down on Mixed Results From Coronavirus Drug Remdesivir

Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.

Regeneron Expands Deal With Intellia for Hemophilia Treatments

Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.

Kinjel Shah headshot

Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates

Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.

Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Mark Vickery headshot

Markets Neutral to Kick Off New Week & Month

Increased levels of stress both at home and abroad aren't exactly being shrugged off by the market, but they're not being particularly negatively affected either.

Market Awaits Major Economic Data This Week

Market Awaits Major Economic Data This Week

Ritujay Ghosh headshot

Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners

Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.

Daniel Laboe headshot

Merck (MRK) Shares Looking Ripe For A Buy

Merck (MRK) is a pharmaceutical powerhouse that has been under-appreciated amid this health crisis

Why Is Gilead (GILD) Down 7.3% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Roche Starts Study on Actemra with Gilead's Drug for Coronavirus

Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.

Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals

Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals

Gilead Inks 10-Year Deal With Arcus for Immuno-oncology Drugs

Gilead (GILD) looks to expand presence in the immune-oncology space with a 10-year partnership with Arcus.

The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

Swayta Shah headshot

3 Top-Ranked Stocks With Upgraded Broker Ratings to Buy Now

It is advisable to follow broker ratings to find attractive stocks, given the uncertain operating backdrop.

Zacks.com headshot

Intercept Down on Postponement of AdCom Meet for NASH Drug

The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.